Karamjit Singh Jandu

Title: Karamjit Singh Jandu: Innovator in LRRK2 Kinase Inhibitors

Introduction

Karamjit Singh Jandu is a notable inventor based in Middlesex, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target LRRK2 kinase activity. With a total of two patents to his name, Jandu's work is particularly relevant in the context of neurodegenerative diseases.

Latest Patents

Jandu's latest patents focus on 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors. The present invention relates to novel compounds that inhibit LRRK2 kinase activity. It also includes processes for their preparation, compositions containing them, and their use in treating diseases characterized by LRRK2 kinase activity, such as Parkinson's disease and Alzheimer's disease. These innovations represent a promising avenue for therapeutic intervention in these debilitating conditions.

Career Highlights

Throughout his career, Karamjit Singh Jandu has worked with prominent companies in the pharmaceutical industry. He has been associated with Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in drug development and patenting.

Collaborations

Jandu has collaborated with several professionals in his field, including Andrew John Eatherton and Oliver James Philps. These collaborations have likely enriched his research and development efforts, leading to innovative solutions in the treatment of diseases.

Conclusion

Karamjit Singh Jandu is a distinguished inventor whose work on LRRK2 kinase inhibitors holds promise for advancing treatments for neurodegenerative diseases. His contributions to the field are significant and reflect his commitment to innovation in medicinal chemistry.